DK2805746T3 - Alkylamido-forbindelser og anvendelser deraf - Google Patents

Alkylamido-forbindelser og anvendelser deraf Download PDF

Info

Publication number
DK2805746T3
DK2805746T3 DK14170446.0T DK14170446T DK2805746T3 DK 2805746 T3 DK2805746 T3 DK 2805746T3 DK 14170446 T DK14170446 T DK 14170446T DK 2805746 T3 DK2805746 T3 DK 2805746T3
Authority
DK
Denmark
Prior art keywords
alkylamido
compounds
alkylamido compounds
Prior art date
Application number
DK14170446.0T
Other languages
English (en)
Inventor
Sergio Baroni
Salvatore Bellinvia
Francesca Viti
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Application granted granted Critical
Publication of DK2805746T3 publication Critical patent/DK2805746T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
DK14170446.0T 2009-02-16 2010-02-16 Alkylamido-forbindelser og anvendelser deraf DK2805746T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09425056 2009-02-16
US17906209P 2009-05-18 2009-05-18
US28746109P 2009-12-17 2009-12-17
EP10708105.1A EP2396081B1 (en) 2009-02-16 2010-02-16 Alkylamido compounds and uses thereof

Publications (1)

Publication Number Publication Date
DK2805746T3 true DK2805746T3 (da) 2020-08-10

Family

ID=42562114

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14170446.0T DK2805746T3 (da) 2009-02-16 2010-02-16 Alkylamido-forbindelser og anvendelser deraf
DK10708105.1T DK2396081T3 (da) 2009-02-16 2010-02-16 Alkylamid-forbindelser og anvendelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10708105.1T DK2396081T3 (da) 2009-02-16 2010-02-16 Alkylamid-forbindelser og anvendelser

Country Status (25)

Country Link
US (11) US8754127B2 (da)
EP (4) EP2396082B1 (da)
JP (4) JP5645851B2 (da)
KR (2) KR101800901B1 (da)
CN (3) CN102316932B (da)
AR (1) AR080596A1 (da)
AU (2) AU2010213095B2 (da)
BR (2) BRPI1008752B1 (da)
CA (2) CA2752623C (da)
CY (2) CY1119225T1 (da)
DK (2) DK2805746T3 (da)
EA (2) EA020198B1 (da)
ES (3) ES2429143T3 (da)
HR (2) HRP20170936T1 (da)
HU (2) HUE032999T2 (da)
IL (2) IL214664A (da)
LT (2) LT2396081T (da)
MX (2) MX2011008602A (da)
NZ (2) NZ595080A (da)
PL (1) PL2396081T3 (da)
PT (3) PT2396081T (da)
SI (2) SI2396081T1 (da)
UA (2) UA105037C2 (da)
WO (2) WO2010091894A2 (da)
ZA (1) ZA201106256B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
EP2396082B1 (en) 2009-02-16 2013-07-31 Nogra Pharma Limited Methods for treating hair related conditions
ES2711100T3 (es) 2011-03-07 2019-04-30 Celgene Corp Métodos para tratar enfermedades usando compuestos isoindolina
EA030762B1 (ru) * 2012-02-09 2018-09-28 Ногра Фарма Лимитед Способы лечения фиброза
US9682050B2 (en) 2012-04-18 2017-06-20 Nogra Pharma Limited Methods of treating lactose intolerance
BR112015005573A2 (pt) * 2012-09-13 2017-07-04 Nogra Pharma Ltd métodos de inibição de crescimento de pelos
EA035986B1 (ru) * 2012-09-13 2020-09-09 Ногра Фарма Лимитед Способы лечения или облегчения плоского фолликулярного лишая
KR101441278B1 (ko) * 2013-11-17 2014-09-17 한규나 머리카락 분말을 이용한 재활용 방법
JP6371520B2 (ja) * 2013-12-26 2018-08-08 日本メナード化粧品株式会社 皮脂合成促進剤
US20180273482A1 (en) 2015-04-06 2018-09-27 The Trustees Of The University Of Pennsylvania Compositions and methods for increasing, or preventing or reversing loss of, skin pigmentation in a mammalian subject
WO2017210600A1 (en) * 2016-06-03 2017-12-07 The Scripps Research Institute Compositions and methods of modulating immune response
WO2020152350A1 (en) * 2019-01-25 2020-07-30 Nogra Pharma Limited Compositions for use in preventing acne
KR20210125047A (ko) 2019-02-08 2021-10-15 노그라 파마 리미티드 3-(4'-아미노페닐)-2-메톡시프로피온산, 및 그의 유사체 및 중간체의 제조 방법
JP6925072B1 (ja) * 2020-12-07 2021-08-25 株式会社Ｄｒ．Ｃｈｅｒｒｙ 毛髪改善のための組成物

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB767788A (en) * 1953-12-28 1957-02-06 Schering Corp Polyiodinated phenyl fatty acid compounds and process for their manufacture
US3211610A (en) 1961-09-29 1965-10-12 Merck & Co Inc Benzoic acid ester derivatives for treating coccidiosis and method of using same
US3444232A (en) 1966-05-18 1969-05-13 Squibb & Sons Inc O-alkyl or phenylalkyl benzohydroxamic acids
GB1359560A (en) 1972-02-25 1974-07-10 Merck & Co Inc Preparation of pyrrylsalicylic acid
US4036951A (en) 1973-03-12 1977-07-19 Synergistics, Inc. Ultra-violet filtration with certain aminosalicylic acid esters
FR2440353A1 (fr) 1978-11-03 1980-05-30 Science Union & Cie Nouveaux arylethanols, leurs procedes d'obtention et leur emploi comme medicament
US4348223A (en) 1980-12-05 1982-09-07 Ppg Industries, Inc. N-Alkyl-N-[3-(alkoxyalkyl)phenyl]-2-haloacetamide herbicides
EP0055689B1 (de) 1980-12-22 1984-07-04 Schering Aktiengesellschaft In 3-Stellung substituierte 2,4,6-trihalogenierte Benzamide und deren Salze, deren Herstellung und Verwendung als Ersatzstoffe für natürliche Süssstoffe sowie Süssungsmittel auf Basis dieser Verbindungen
JPS58194814A (ja) 1982-05-11 1983-11-12 Nippon Shinyaku Co Ltd 免疫調節作用を有する薬剤
IL69282A (en) 1982-09-02 1988-06-30 Euro Celtique Sa Method for the carboxylation of potassium phenoxide with carbon dioxide
GB8302708D0 (en) 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
DE3786452T2 (de) 1987-02-05 1993-10-21 Kureha Chemical Ind Co Ltd Benzylether-Verbindungen und Verfahren zu ihrer Herstellung.
US4933330A (en) 1987-04-01 1990-06-12 Dak-Laboratoriet Benzoic acid derivatives and use thereof
ES2065980T3 (es) 1988-05-05 1995-03-01 Tillotts Pharma Ag Uso del acido 5-aminosalicilico en el tratamiento de alteraciones dermatologicas.
CA2090220C (en) 1990-10-22 2003-07-08 Thomas Julius Borody Treatment of non-inflammatory and non-infectious bowel disorders
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
US5262549A (en) 1991-05-30 1993-11-16 Polaroid Corporation Benzpyrylium dyes, and processes for their preparation and use
US5302751A (en) 1992-01-21 1994-04-12 Ethyl Corporation Profen resolution
PT634408E (pt) 1992-03-17 2002-05-31 Fujisawa Pharmaceutical Co Derivado de depsipeptido sua producao e utilizacao
AU674330B2 (en) 1992-06-30 1996-12-19 Howard K. Shapiro Composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
EP0759750A4 (en) 1994-05-11 1998-05-27 Howard K Shapiro PREPARATIONS FOR TREATING CHRONIC FLAMMABLE DISEASES
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
JPH10511097A (ja) 1995-03-28 1998-10-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 低薬用量リドグレル調合物および炎症性腸疾患の処置のためのそれらの使用
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9617001D0 (en) 1996-08-13 1996-09-25 Tillotts Pharma Ag Oral composition
DE19647582A1 (de) 1996-11-18 1998-05-20 Hoechst Ag Verfahren zur Herstellung von aromatischen Olefinen mittels Katalyse durch Palladaphosphacyclobutane
AU6773598A (en) 1997-03-26 1998-10-20 Institut Pasteur Treatment of gastrointestinal disease with ppar modulators
AU8588798A (en) 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
WO1999015520A1 (fr) 1997-09-19 1999-04-01 Ono Pharmaceutical Co., Ltd. Composes de benzene fusionnes ou non fusionnes
US7015249B1 (en) 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6114382A (en) 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
FR2791671B1 (fr) * 1999-04-01 2001-05-11 Oreal Nouveaux composes derives d'esters d'acide benzoique, composition les comprenant et utilisation
GB9908647D0 (en) 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
US20040034067A1 (en) 1999-04-15 2004-02-19 Macphee Colin Houston Novel method of treatment
GB9914371D0 (en) 1999-06-18 1999-08-18 Smithkline Beecham Plc Novel compounds
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
US6369098B1 (en) 1999-10-05 2002-04-09 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US7736661B1 (en) 2000-03-07 2010-06-15 Avon Products, Inc Method of treating skin conditions
DK1274675T3 (da) 2000-04-19 2004-12-06 Neurotech Co Ltd Forbindelser, sammensætninger og fremgangsmåder til forebyggelse af neurodegeneration ved akutte og kroniske skader i centralnervesystemet
US7049342B2 (en) 2000-05-29 2006-05-23 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropionic acid derivatives
DE60135742D1 (de) * 2000-05-29 2008-10-23 Kyorin Seiyaku Kk Substituierte phenylpropionsäure-derivate
AU2001285311B2 (en) 2000-08-29 2005-09-15 Biocon, Ltd Immunoregulatory compounds, derivatives thereof and their use
EP1348698A4 (en) 2000-12-05 2005-01-19 Kyorin Seiyaku Kk SUBSTITUTED CARBOXYLENE DERIVATIVES
FR2822955B1 (fr) 2001-03-27 2003-10-03 Chru Lille Methode de diagnostic de maladies inflammatoires chroniques de l'intestin
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
EP1389044A4 (en) 2001-04-18 2006-07-05 Merck & Co Inc PPAR-ALPHA-GAMMA AGONISTS OR LIGANDS FOR THE TREATMENT OF INFLAMMATIONS
CA2354921A1 (en) 2001-05-24 2002-11-24 Yasuo Konishi Drug evolution: drug design at hot spots
IL161429A0 (en) 2001-10-16 2004-09-27 Reddys Lab Ltd Dr Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing the same
AU2002357729A1 (en) 2001-11-16 2003-06-10 Nutrition 21, Inc. Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
AU2002343094A1 (en) 2001-11-26 2003-06-10 Arachnova Therapeutics Ltd. Use of ppar activators for the treatment of pulmonary fibrosis
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
US20030113815A1 (en) 2001-12-19 2003-06-19 Pfizer Inc. Canine peroxisome proliferator activated receptor gamma
WO2003053974A1 (en) 2001-12-21 2003-07-03 Dr. Reddy's Laboratories Ltd. Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US20030220374A1 (en) 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040115127A1 (en) 2002-04-12 2004-06-17 Wright Samuel D. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
US8492438B2 (en) 2002-04-26 2013-07-23 Asan Laboratories Company (Cayman), Limited Treatment skin disorders
AU2003228744A1 (en) 2002-04-29 2003-11-17 The Ohio State University Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20060159648A1 (en) 2003-02-17 2006-07-20 Davis Adrian F Novel therapeutic method and compositions for topical administration
GB0303609D0 (en) 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
EP1607103A1 (en) 2003-03-20 2005-12-21 Eisai Co., Ltd. Concomitant drug as therapeutic agent for inflammatory bowel disease
ES2337150T3 (es) 2003-07-21 2010-04-21 Merck Serono Sa Alquinilaril carboxamidas.
UA60954C2 (en) 2003-07-25 2006-03-15 Subsidiary Entpr With Foreign Method for measuring conductivity of electrolyte by a contactless measuring transducer
US7749980B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for treating pain
WO2005040102A2 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd. Novel compounds and their use as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
FR2862870A1 (fr) 2003-12-01 2005-06-03 Galderma Res & Dev Utilisation d'activateurs de recepteurs ppar en cosmetique et dermatologie.
JP2007513173A (ja) 2003-12-03 2007-05-24 スミスクライン・ビーチャム・コーポレイション ロシグリタゾンを用いる乾癬の治療
US7417037B2 (en) 2004-01-20 2008-08-26 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
WO2005084658A1 (en) * 2004-03-04 2005-09-15 Arakis Ltd. Derivatives of actarit and their therapeutic use
US20050277693A1 (en) 2004-06-10 2005-12-15 Dr. Reddy's Laboratories Limited Basic salts and monohydrates of certain alpha, beta-propionic acid derivative
PE20060594A1 (es) 2004-09-09 2006-08-18 Novartis Ag Composicion farmaceutica que contiene un agonista de ppar
AU2005289453A1 (en) 2004-09-27 2006-04-06 Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health Modulating MxA expression
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
EP1719543A1 (en) 2005-05-04 2006-11-08 Asan Labs., Ltd. Use of histone deacetylase inhibitors for the treatment of gastrointestinal distress
US20060270635A1 (en) 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
DE102005061472A1 (de) 2005-12-22 2007-07-05 Saltigo Gmbh Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-phenylpropionsäuren
WO2007096148A1 (en) 2006-02-23 2007-08-30 Lipid Nutrition B.V. Immunoregulation
US7645801B2 (en) 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
IE20070129A1 (en) * 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
US8796282B2 (en) 2007-03-28 2014-08-05 Case Western Reserve University Method of treating dermatological disorders
WO2009025854A1 (en) 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
US8030520B2 (en) 2008-03-31 2011-10-04 Saltigo Gmbh Process for preparing organic compounds by a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
EP2396082B1 (en) 2009-02-16 2013-07-31 Nogra Pharma Limited Methods for treating hair related conditions
EP2298321A1 (en) 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
CA2841358A1 (en) 2011-07-15 2013-01-24 S.L.A. Pharma Ag Pharmaceutical compositions for rectal administration
WO2013059364A2 (en) 2011-10-17 2013-04-25 The Regents Of The University Of California Methods for assessing repellant quality of organic materials and methods and compositions for repelling arthropods
US9809557B2 (en) 2011-10-31 2017-11-07 Claus Selch Larsen Prodrugs of non-steroid anti-inflammatory agents (NSAIDS)
EA030762B1 (ru) 2012-02-09 2018-09-28 Ногра Фарма Лимитед Способы лечения фиброза
US9682050B2 (en) 2012-04-18 2017-06-20 Nogra Pharma Limited Methods of treating lactose intolerance
WO2013168438A1 (ja) 2012-05-10 2013-11-14 国立大学法人岩手大学 ラクターゼ活性を有するタンパク質、該タンパク質をコードする遺伝子、該遺伝子を含有する組み換えベクター、形質転換体、及びその製造方法並びに用途
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
CN104619687A (zh) 2012-06-01 2015-05-13 诺格拉制药有限公司 能够调节t-细胞应答的双环杂环及其使用方法
CA2985787A1 (en) 2012-06-07 2013-12-12 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
EA035986B1 (ru) 2012-09-13 2020-09-09 Ногра Фарма Лимитед Способы лечения или облегчения плоского фолликулярного лишая
BR112015005573A2 (pt) 2012-09-13 2017-07-04 Nogra Pharma Ltd métodos de inibição de crescimento de pelos
PT2978416T (pt) 2013-03-26 2016-12-09 Lipid Therapeutics Gmbh Formulação farmacêutica compreendendo fosfatidilcolina para o tratamento de colite ulcerosa
CN105566153B (zh) 2014-10-14 2019-05-31 中国医学科学院药物研究所 偶氮苯衍生物及其制法和药物组合物与用途
US20180193361A1 (en) 2015-04-02 2018-07-12 University Health Network Gut anti-inflammatory agents for regulation of high blood glucose levels
EP3307262B1 (en) 2015-06-15 2021-05-19 NMD Pharma A/S Compounds for use in treating neuromuscular disorders
WO2017046343A1 (en) 2015-09-17 2017-03-23 Nogra Pharma Limited Compositions for rectal administration in the treatment of ulcerative colitis and methods of using same
WO2017093444A1 (en) 2015-12-01 2017-06-08 Nogra Pharma Limited Compositions for oral administration in the treatment of inflammatory bowel disease
EP3419616A1 (en) 2016-02-26 2019-01-02 Nogra Pharma Limited Methods of treating lactose intolerance

Also Published As

Publication number Publication date
BRPI1008752A2 (pt) 2016-03-08
EP2396081A2 (en) 2011-12-21
AU2010213095B2 (en) 2015-09-17
US10398667B2 (en) 2019-09-03
CA2752626A1 (en) 2010-08-19
ES2806691T3 (es) 2021-02-18
US9901557B2 (en) 2018-02-27
US20120053244A1 (en) 2012-03-01
HUE032999T2 (hu) 2017-11-28
EA201171063A1 (ru) 2012-01-30
CA2752623C (en) 2017-07-04
BRPI1011226A2 (pt) 2016-03-15
EA201171062A1 (ru) 2012-01-30
EP2396082A2 (en) 2011-12-21
JP5645851B2 (ja) 2014-12-24
EA020856B1 (ru) 2015-02-27
DK2396081T3 (da) 2017-07-10
EP2396082B1 (en) 2013-07-31
CN102316931A (zh) 2012-01-11
HRP20170936T1 (hr) 2017-09-22
IL214664A (en) 2015-09-24
SI2805746T1 (sl) 2020-10-30
BRPI1011226B1 (pt) 2019-10-29
HRP20201184T1 (hr) 2020-12-11
AU2010213095A1 (en) 2011-09-08
IL214665A0 (en) 2011-09-27
JP5715070B2 (ja) 2015-05-07
US20200383942A1 (en) 2020-12-10
SI2396081T1 (sl) 2017-09-29
IL214664A0 (en) 2011-09-27
KR101800901B1 (ko) 2017-11-23
HUE050267T2 (hu) 2020-11-30
US20200188340A1 (en) 2020-06-18
US9511041B2 (en) 2016-12-06
CN102316932A (zh) 2012-01-11
AU2010213093B2 (en) 2016-01-07
US8754127B2 (en) 2014-06-17
WO2010091894A2 (en) 2010-08-19
US20150148418A1 (en) 2015-05-28
EA020198B1 (ru) 2014-09-30
US20220354809A1 (en) 2022-11-10
WO2010091892A3 (en) 2010-10-21
US10137101B2 (en) 2018-11-27
US20120053245A1 (en) 2012-03-01
MX2011008601A (es) 2011-09-09
KR101776337B1 (ko) 2017-09-07
US20170172956A1 (en) 2017-06-22
PT2396082E (pt) 2013-10-03
WO2010091894A3 (en) 2010-11-11
AR080596A1 (es) 2012-04-25
JP5820030B2 (ja) 2015-11-24
CN104666288B (zh) 2017-08-04
WO2010091892A2 (en) 2010-08-19
JP2015155427A (ja) 2015-08-27
IL214665A (en) 2017-02-28
PL2396081T3 (pl) 2017-10-31
ES2429143T3 (es) 2013-11-13
CN104666288A (zh) 2015-06-03
MX2011008602A (es) 2011-09-09
US20160338927A1 (en) 2016-11-24
US20180369178A1 (en) 2018-12-27
PT2805746T (pt) 2020-08-17
JP2012517969A (ja) 2012-08-09
CA2752623A1 (en) 2010-08-19
US10959970B2 (en) 2021-03-30
NZ595080A (en) 2013-09-27
US8796334B2 (en) 2014-08-05
BRPI1008752B1 (pt) 2020-02-11
EP2396081B1 (en) 2017-04-05
CY1119225T1 (el) 2018-02-14
JP2012517968A (ja) 2012-08-09
UA109525C2 (xx) 2015-09-10
ES2630044T3 (es) 2017-08-17
KR20110120945A (ko) 2011-11-04
PT2396081T (pt) 2017-07-11
AU2010213093A1 (en) 2011-09-08
KR20110120946A (ko) 2011-11-04
LT2396081T (lt) 2017-09-11
LT2805746T (lt) 2020-09-25
EP2805746B1 (en) 2020-05-06
CN102316932B (zh) 2014-07-09
US20190269637A1 (en) 2019-09-05
US20150051285A1 (en) 2015-02-19
ZA201106256B (en) 2012-05-30
EP2805746A1 (en) 2014-11-26
CN102316931B (zh) 2014-11-19
CA2752626C (en) 2018-03-27
CY1123213T1 (el) 2021-12-31
UA105037C2 (uk) 2014-04-10
JP2014237692A (ja) 2014-12-18
NZ595076A (en) 2013-09-27
EP3744398A1 (en) 2020-12-02

Similar Documents

Publication Publication Date Title
DK2805746T3 (da) Alkylamido-forbindelser og anvendelser deraf
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
DK2594567T3 (da) Heterocykliske alkynylbenzenforbindelser og anvendelser deraf
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
DK3292874T3 (da) Anti-mesothelin-immunkonjugater og anvendelser deraf
IT1400767B1 (it) Microsistema
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK2086213T3 (da) Billedlæseapparat og billeddannelseapparat
DK2401239T3 (da) Pulverformet isoleringsmørtel og lagdelt isoleringsmørtel
DK2642992T3 (da) Forbindelser og anvendelse deraf
DK2475649T3 (da) Indenonderivat og farmaceutisk sammensætning omfattende samme
DK2536591T3 (da) Advarselslysanordning; komponenter; og fremgangsmåder
DK2226545T3 (da) Rørelement og anvendelse heraf
DK2320888T3 (da) Laidlomycinsammensætninger og fremgangsmåder
DK2310037T3 (da) Conglutin-gamma as-medikament og -kosttilskudpatentkrav
DK2576910T3 (da) Fremgangsmåde og element
FI9141U1 (fi) Apuväline
TH129804B (th) องค์ประกอบที่ใช้ภายนอก
TH0901000558A (th) สารผสมและอุปกรณ์
FI8702U1 (fi) Apuväline
TH108455B (th) หน้าตัด
TH108457B (th) หน้าตัด
TH108459B (th) หน้าตัด
TH108460B (th) หน้าตัด
TH108456B (th) หน้าตัด